Abstract Number: 389 • 2018 ACR/ARHP Annual Meeting
Risk Factors Associated with Mortality in Inflammatory Myositis: An Asian Perspective
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune diseases with systemic involvement and excess mortality. We aim to describe the causes and…Abstract Number: 2936 • 2018 ACR/ARHP Annual Meeting
Esophageal Erosion Predicts Progression of Lung Disease in Patients with Systemic Sclerosis
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in Systemic Sclerosis (SSc) but its pathogenesis is not fully understood. Esophageal disease is…Abstract Number: 525 • 2018 ACR/ARHP Annual Meeting
Low Interstitial Lung Disease Event Rate in Patients with Rheumatoid Arthritis: Pooled Post Hoc Analysis of Data from the Tofacitinib Clinical Development Program
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Interstitial lung disease (ILD) is a common extra-articular manifestation of RA,1 and…Abstract Number: 2979 • 2018 ACR/ARHP Annual Meeting
Innovative Approaches for the Assessment of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Ultrasound Evaluation of Pleural Irregularities and Semiquantitative and Quantitative Analysis of Lung CT
Background/Purpose: Interstitial Lung Disease (ILD) in patients with Idiopathic Inflammatory Myopathies (IIM) is associated to high mortality and morbidity. The study of pleural irregularities (PI)…Abstract Number: 528 • 2018 ACR/ARHP Annual Meeting
Progression in Interstitial Lung Disease – Comparison of Rheumatoid Arthritis with Idiopathic Pulmonary Fibrosis
Background/Purpose: Rheumatoid Arthritis (RA) is a common autoimmune condition characterised by symmetrical inflammatory small joint polyarthropathy and loss of function. Systemic manifestations of RA are…Abstract Number: 791 • 2018 ACR/ARHP Annual Meeting
Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients
Background/Purpose: Studies from our laboratory and others have shown thrombin to be a fibrogenic mediator implicated in the pathogenesis of ILD, including scleroderma-associated ILD (SSc-ILD).…Abstract Number: 800 • 2018 ACR/ARHP Annual Meeting
Assessment of Recent Evidence to Support Treatment Recommendations in Patients with SSc-ILD
Background/Purpose: Systemic Sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis of skin and internal organs with an estimated worldwide prevalence of 110-430 cases/million.…Abstract Number: 884 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Disease Activity Predicting Incident Clinically-Apparent Interstitial Lung Disease: A Prospective Cohort Study
Background/Purpose: Determining modifiable risk factors for interstitial lung disease (ILD) is crucial given its substantial morbidity/mortality. Treatment to target of remission/low disease activity improves articular…Abstract Number: 1013 • 2018 ACR/ARHP Annual Meeting
Circulating Hybrid M1/M2 Monocytes/Macrophages in Systemic Sclerosis Patients with Lung Involvement
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by immune system alterations, vasculopathy and fibrosis [1]. SSc-related interstitial lung disease (ILD) represents a common…Abstract Number: 1309 • 2018 ACR/ARHP Annual Meeting
Interstitial Pneumonia with Autoimmune Features: Is It Frequent?
Background/Purpose: A particular subset of interstitial pneumonia, associated to one or more clinical and serological features, suggesting a possible underlying autoimmune disorder, has been described…Abstract Number: 1331 • 2018 ACR/ARHP Annual Meeting
Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene 5 Syndrome
Background/Purpose: Dermatomyositis (DM) is a heterogenous group of diseases ranging from skin limited disorders to non-specific auto-immune diseases with patients suffering from additional extra-cutaneous manifestations.…Abstract Number: 2173 • 2017 ACR/ARHP Annual Meeting
Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies
Background/Purpose: The anti-melanoma differentiation-associated gene 5 antibody (MDA5) was recently classified as a myositis-specific antibody (MSA), and has been associated with rapidly progressive interstitial lung…Abstract Number: 98 • 2017 ACR/ARHP Annual Meeting
Impact of a Lung Ultrasound Course for Rheumatology Specialist (IMPACT-2)
Background/Purpose: Although much emphasis is focused on lung ultrasonography(US) within the critical care field, there is a growing interest in the use of lung…Abstract Number: 2392 • 2017 ACR/ARHP Annual Meeting
Impact of the Pattern of Interstitial Lung Disease on Mortality in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
ABSTRACT Impact of the Pattern of Interstitial Lung Disease on Mortality in Rheumatoid Arthritis: A systematic review and meta-analysis Background/Purpose: Interstitial lung disease affects 10-15%…Abstract Number: 257 • 2017 ACR/ARHP Annual Meeting
The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis
Background/Purpose: Interstitial lung disease (ILD) in systemic sclerosis is treated by immunosuppressive drugs (e.g. cyclophosphamide), aimed at reduction of inflammatory response . Differentiation between inflamed…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 39
- Next Page »